Cytochroma

DIVERSE DONORS,

CONSISTENT RESULTS

DIVERSE

DONORS,

CONSISTENT

RESULTS

DIVERSE

DONORS,

CONSISTENT

RESULTS

Advanced organoids, diverse donors and Wet AI™

What Cytochroma Does

Cytochroma provides optimised cell models, high throughput screening and powerful data for superior drug discovery and validation.

We offer every cell type from every donor, allowing comprehensive, donor-matched model systems across diverse populations and diseases.

Cytochroma’s large scale Wet AI™ facilities can generate rich phenotypic data and tackle the complexity of human biology in drug discovery.

Key Highlights

01

Optimised Cell Models:

Cytochroma offers a range of iPSC-derived cell types from genetically diverse male and female donors, optimised for HTP screening or combine to form multicellular models of health and disease.

01

Optimised Cell Models:

Cytochroma offers a range of iPSC-derived cell types from genetically diverse male and female donors, optimised for HTP screening or combine to form multicellular models of health and disease.

02

Every Cell Type, Every Donor:

Discover the widest library of commercially available hepatic and cardiac iPS derived cell types, representing a global population and aligning with FDA recommendations to improve inclusivity in drug development.

02

Every Cell Type, Every Donor:

03

Cytochroma Wet AI™:

Through large-scale wet-lab experiments and machine learning Cytochroma is building data sets that harnesses the complexity and diversity of human biology, driving faster more advanced drug discovery.

03

Cytochroma Wet AI™:

Leaders in Science, Pioneers in diversity

Why we need increased diversity in preclinical testing

Cytochroma offers one of the most genetically diverse panels of iPSC-derived human cell models available—providing matched cell types from both male and female donors across a range of ethnic backgrounds. This level of diversity is unmatched in the market.
Regulatory agencies like the FDA increasingly require evidence that new drugs are safe and effective across different patient populations. By using multiple, diverse donors from the earliest stages of preclinical testing, Cytochroma enables more predictive, translatable data—reducing risk of failure in later clinical trials and supporting regulatory approval.

Our donor-matched, multi-lineage panels allow pharma teams to assess variability in drug response and toxicity upfront—accelerating the development of safer, more inclusive medicines.

Regulatory requirements

Regulatory bodies are increasingly emphasising the importance of including both genders and diverse genetic backgrounds in preclinical studies. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued guidelines encouraging more representative preclinical research. Complying with these guidelines not only expedites the drug approval process but also ensures that the drug's safety and efficacy are thoroughly evaluated across varied populations.

With the FDA Modernization Act 3.0 supporting non-animal testing, pharma and biotech are rethinking preclinical development. While others are just adapting, Cytochroma's flexible, human-relevant approach aligns its assays and models to the specific biology, disease context, and regulatory goals—empowering teams to generate meaningful data earlier and de-risk decision making.

Incorporate diversity into your drug development journey

Contact us today to find out more about our diverse stem cell library and how it can help de-risk your drug development, predict adverse reactions early on and ensure clinical success.